Location History:
- Tsukuba, JP (1990 - 1998)
- Yuki-gun, JP (2001)
- Ibaraki, JP (2001)
- Ishigemachi, JP (1996 - 2002)
- Osaka, JP (2004 - 2007)
- Chuo-ku, JP (2010)
Company Filing History:
10 out of 940 
3 out of 417 
Years Active: 1990-2010
Title: Takehiko Ohkawa: Innovator in Pharmaceutical Chemistry
Introduction
Takehiko Ohkawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various diseases. With a total of 13 patents to his name, Ohkawa's work has had a substantial impact on therapeutic options available for patients.
Latest Patents
One of his latest patents is for a triazole derivative or salt thereof. This compound is designed for the therapy of diseases in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) participates, particularly diabetes and insulin resistance. The triazole derivative, which features a trisubstituted methyl group in the 2-position, exhibits strong 11β-HSD1 inhibitory activity. Additionally, this compound has demonstrated an excellent blood-glucose level-lowering action, making it a promising candidate for diabetes therapy. Another notable patent is for a 2-cyanopyrrolidinecarboxamide compound, which is also a pharmaceutically acceptable salt.
Career Highlights
Throughout his career, Takehiko Ohkawa has worked with esteemed organizations such as Fujisawa Pharmaceutical Company, Ltd. and Astellas Pharma GmbH. His experience in these companies has allowed him to refine his expertise in pharmaceutical development and innovation.
Collaborations
Ohkawa has collaborated with notable colleagues, including Teruo Kyoto Oku and Hiroyuki Setoi. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Takehiko Ohkawa's contributions to pharmaceutical chemistry are noteworthy, with his innovative patents addressing critical health issues such as diabetes and insulin resistance. His work continues to influence the field and offers hope for improved therapeutic options.